Lv3
210 积分 2025-07-07 加入
Novel Linkers and Connections for antibody–drug Conjugates to Treat Cancer and Infectious Disease
16天前
已关闭
Novel Linkers and Connections for antibody–drug Conjugates to Treat Cancer and Infectious Disease
16天前
已关闭
Novel Linkers and Connections for antibody–drug Conjugates to Treat Cancer and Infectious Disease
16天前
已关闭
A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors
20天前
已关闭
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies
20天前
已完结
Abstract PR009: The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents
20天前
已完结
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
30天前
已完结
Linker Design for the Antibody Drug Conjugates: A Comprehensive Review
30天前
已完结
Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001
1个月前
已完结
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance
1个月前
已完结
皖公网安备34019202002308
